The illicit drug supply rarely stays still. As one novel substance becomes widely recognized or controlled, a closely related compound can begin appearing alongside it, or taking its place.
That appears to be happening with bromazolam and a newer designer benzodiazepine called phenazolam, also known as clobromazolam.
Bromazolam has not disappeared from the drug supply. However, the Drug Enforcement Administration temporarily placed it in Schedule I on March 16, 2026, with the order currently effective through March 16, 2028. Even before that federal action, forensic researchers had warned that bromazolam detections could decline as the illicit market shifted toward other novel benzodiazepines, including phenazolam.
The transition may already be underway in Tennessee. Aegis Sciences reported that, among samples it received during the third quarter of 2025, phenazolam was detected more frequently than other designer benzodiazepines in Tennessee and four other states.
For people purchasing counterfeit pills, powders, or drugs through unregulated sources, this market shift may be almost impossible to see. A substance sold under one name can contain a different benzodiazepine, or several drugs mixed together.
Phenazolam (Clobromazolam) at a Glance
| Category | Information |
|---|---|
| Drug Name | Phenazolam |
| Also Known As | Clobromazolam |
| Drug Class | Designer benzodiazepine (novel benzodiazepine) |
| DEA Status (U.S.) | Not federally scheduled as of August 2026 (status may change) |
| Approved Medical Use | None |
| Prescription Available? | No |
| Common Forms | Counterfeit tablets, pressed pills, powder, capsules |
| Street Market | Sold as a standalone designer benzo or misrepresented as Xanax or bromazolam |
| Primary Effects | Sedation, anxiety relief, muscle relaxation, amnesia, drowsiness |
| Onset | Unknown in humans; likely similar to other potent designer benzodiazepines |
| Duration | Not well established; may be prolonged due to high potency |
| Overdose Risk | High when combined with opioids, alcohol, xylazine, nitazenes, or other CNS depressants |
| Addiction Potential | High |
| Withdrawal Risk | High; sudden discontinuation may cause seizures, delirium, and life-threatening withdrawal |
| Detected In | Counterfeit pills, illicit powders, and polysubstance drug mixtures |
| Common Co-Occurring Drugs | Fentanyl, nitazenes, heroin, xylazine, medetomidine, bromazolam, stimulants |
| Can Narcan Reverse It? | No. Naloxone only reverses opioid effects but should still be administered if opioid exposure is suspected. |
| Drug Test Detection | May trigger a benzodiazepine screen, but specialized laboratory testing may be needed to specifically identify phenazolam. |
What Is Phenazolam?
Phenazolam is a synthetic benzodiazepine classified as a novel psychoactive substance, sometimes called a designer benzodiazepine. It was first synthesized in the 1980s as a potential pharmaceutical but was never approved for therapeutic use.
The name clobromazolam generally refers to the same substance. According to the Center for Forensic Science Research and Education, that nickname comes from phenazolam’s chemical structure: it is closely related to bromazolam but contains an additional chlorine atom on its benzene ring. The name has appeared in online drug markets and user forums even though forensic laboratories generally refer to the compound as phenazolam.
Human research remains extremely limited. There is no established medical dosage, standardized pharmaceutical product, approved therapeutic use, or reliable dose conversion between phenazolam and prescription drugs such as Xanax.
| Name | What It Means |
|---|---|
| Phenazolam | The name commonly used in forensic and toxicology reporting for this emerging designer benzodiazepine |
| Clobromazolam | An alternate market or forum name for phenazolam; it is not a separate drug |
| Bromazolam | A closely related but distinct designer benzodiazepine temporarily placed in federal Schedule I |
| Phenazepam | A different benzodiazepine with a similar-sounding name; it should not be confused with phenazolam |
Forensic research evaluates phenazepam and clobromazolam as separate compounds, despite the similarity between their names.
Why Is Phenazolam Rising Now?
Phenazolam’s emergence appears to be part of a familiar pattern in the novel-drug market. When one chemical becomes controlled, harder to obtain, or easier for laboratories to identify, suppliers may turn to a structurally similar substance that is less familiar to consumers, clinicians, and toxicology laboratories.
In December 2025, CFSRE reported that phenazolam positivity had increased overall since 2024, including a noticeable upward trend from the first through third quarters of 2025. Its researchers specifically predicted that bromazolam detections would decline as the drug was replaced within portions of the illicit supply by novel benzodiazepines such as phenazolam.
The federal scheduling of bromazolam did not create the phenazolam trend by itself. Aegis was already seeing phenazolam surpass other designer benzodiazepines in some states months before the March 2026 scheduling order. Federal controls may, however, place additional pressure on illicit manufacturers and distributors to move toward related compounds.
This should not be interpreted as a complete one-for-one replacement. Current data show bromazolam and phenazolam circulating at the same time, and some toxicology specimens have contained both drugs. The better description is that the designer-benzo market is diversifying, with phenazolam emerging as one of the most important substances to watch.
Why Phenazolam Is a Particular Concern in Tennessee
Two different testing programs have now identified phenazolam as a developing issue in Tennessee.
Aegis reported that phenazolam was the most frequently identified designer benzodiazepine in the Tennessee samples it received during the third quarter of 2025. Kentucky, New Jersey, Ohio, and Oregon showed the same pattern.
The DEA’s first-quarter 2026 TOX report subsequently identified phenazolam in four biological samples associated with fatal cases. Three of those samples came from Tennessee, while one came from Utah. The same report identified bromazolam in five fatal-case samples, including four from Tennessee.
These are small, selected surveillance datasets. They do not measure how many people across Tennessee are using phenazolam, and a drug’s presence in a fatal case does not prove that it caused the death by itself. Many toxicology cases involve multiple substances.
However, when separate laboratory systems identify the same emerging compound in Tennessee—and both phenazolam and bromazolam are appearing in fatal-case testing—it provides an important early warning for individuals, families, treatment providers, emergency departments, and first responders.
Why Phenazolam May Be More Dangerous Than Its Name Suggests
Phenazolam may sound like just another version of bromazolam. In reality, small chemical changes can significantly affect how a designer benzodiazepine interacts with the brain, how much sedation it produces, and how long its effects last.
Its potency is not well understood
A peer-reviewed study using chemical modeling predicted that clobromazolam had greater binding affinity at GABA-A receptors than designer benzodiazepines previously evaluated by the researchers. Greater predicted binding affinity may indicate greater potency, but this was not a controlled human dosing study. It cannot tell someone that a particular amount of phenazolam equals a particular amount of Xanax, Klonopin, Valium, or bromazolam.
Any website, seller, or forum offering a precise phenazolam dose conversion should therefore be treated with caution. Illicit products are not standardized, and the amount listed on a package may bear little relationship to what is actually present.
It is appearing in complex drug mixtures
CFSRE identified phenazolam in 11 blood specimens and 33 drug-material samples during 2025. It appeared both alone and alongside other benzodiazepines, opioids, stimulants, and hallucinogens.
Tested powders containing phenazolam also contained substances such as fentanyl, heroin, nitazene opioids, medetomidine, and xylazine. Phenazolam was also identified in illicit tablet samples.
This creates several possible scenarios:
- Someone may intentionally purchase what they believe is a designer benzodiazepine without knowing its true potency.
- Someone may expect bromazolam but receive phenazolam instead.
- Someone seeking an opioid or stimulant may unknowingly consume phenazolam as an adulterant.
- A single powder or tablet may contain several respiratory depressants.
The risk is not limited to people intentionally searching for phenazolam.
Sedation and memory loss can be profound
Reported concerns associated with novel benzodiazepines include strong sedation, amnesia, dizziness, blurred vision, slurred speech, muscle relaxation, and loss of coordination. These effects can contribute to falls, impaired driving, accidents, vulnerability to assault, and an inability to recognize that an overdose is developing.
A person may remain awake long enough to take additional pills or use another drug, then have little or no memory of doing so.
Opioids and alcohol dramatically increase the danger
Benzodiazepines and opioids both suppress the central nervous system. When taken together, they can produce deeper sedation and more serious respiratory depression than either substance alone. Alcohol, sleep medications, and other sedatives can further increase that risk.
This is especially concerning when phenazolam is already being identified in drug mixtures containing fentanyl, heroin, nitazenes, and other powerful depressants.
Routine drug testing may not identify the exact compound
Designer benzodiazepines can complicate routine toxicology testing. A standard benzodiazepine screening test may react to a novel compound, but a traditional confirmation panel may not include that specific drug. This can result in an apparent positive screen that is not fully explained by the laboratory’s standard confirmation testing.
Specialized testing may be required to distinguish phenazolam from bromazolam, prescription benzodiazepines, and other emerging analogues. Families should not assume that an inconclusive routine test means no illicit benzodiazepine was involved.
Signs of Phenazolam Intoxication or Overdose
Because phenazolam has not been adequately studied in humans, there is no single symptom pattern that can definitively identify it without laboratory testing. Warning signs of serious benzodiazepine intoxication may include:
- Extreme sleepiness or inability to remain awake
- Difficulty waking the person
- Slurred or incoherent speech
- Confusion or severe memory loss
- Stumbling and loss of coordination
- Limp muscles or inability to sit upright
- Slow, shallow, irregular, or stopped breathing
- Blue, gray, or pale lips and fingertips
- Vomiting while unconscious
- Gurgling, choking, or snoring-like sounds from an unresponsive person
Severe breathing problems are particularly concerning when an opioid, alcohol, or another depressant may also be involved.
What to Do During a Suspected Overdose
Do not assume that an extremely sedated person simply needs to “sleep it off.”
- Call 911 immediately. Tell the dispatcher what substances may have been taken, while making it clear that the contents are uncertain.
- Administer naloxone if opioid exposure is possible. Naloxone does not reverse phenazolam or other benzodiazepines, but it can reverse the opioid portion of a mixed overdose.
- Stay with the person. Follow the dispatcher’s instructions, support breathing, and provide rescue breathing or CPR when trained or directed to do so.
- Place a breathing but unconscious person on their side. This can help reduce the risk of choking if vomiting occurs.
A person may begin breathing better after naloxone but remain profoundly sedated because the benzodiazepine effects are still present. Emergency medical care is still necessary.
Can Phenazolam Cause Dependence and Withdrawal?
Phenazolam is expected to carry the same general physical-dependence concerns as other benzodiazepines. Repeated benzodiazepine exposure causes the brain to adapt to increased GABA activity. When the drug is suddenly removed, the nervous system can become dangerously overactive.
Withdrawal may involve worsening anxiety, panic, insomnia, sweating, tremors, nausea, agitation, memory problems, perceptual disturbances, hallucinations, delirium, or seizures. The FDA warns that abruptly stopping benzodiazepines or reducing them too quickly can cause life-threatening withdrawal reactions, including seizures.
ASAM similarly recommends that people who have used benzodiazepines regularly should not abruptly discontinue them. A gradual, individualized taper under clinical supervision is generally safer.
Phenazolam creates an additional problem: a person may not know the strength of the product, the amount used, or whether the pills also contained bromazolam, alprazolam, opioids, or other substances. This makes online taper schedules and unofficial dose-conversion charts especially unreliable.
Someone experiencing seizures, hallucinations, severe confusion, psychosis, difficulty breathing, or thoughts of harming themselves or others needs emergency medical attention.
Treatment for Phenazolam and Designer-Benzo Use in Tennessee
You do not need to know the exact chemical in every pill before asking for help.
At Brooks Healing Center, treatment can begin with an assessment of the substances being used, withdrawal history, current symptoms, co-occurring opioid or alcohol use, and underlying concerns such as anxiety, trauma, insomnia, or depression.
Depending on the person’s needs, care may include:
- Medical detox with access to medical and clinical support
- An individualized stabilization or tapering plan
- Residential addiction treatment
- Individual and group therapy
- Treatment for co-occurring mental health conditions
- Education about counterfeit pills and polysubstance overdose
- Relapse-prevention and continuing-care planning
Brooks provides 24/7 access to medical and clinical care during its detox level of care, with residential and dual-diagnosis services available to support continued stabilization and recovery.
Phenazolam may be a new name, but the fear, dependence, withdrawal, and loss of control surrounding its use are treatable. Reaching out early can help prevent the next counterfeit pill, unexpected mixture, or abrupt withdrawal from becoming a medical emergency.
CALL BROOKS HEALING CENTER or VERIFY YOUR INSURANCE to get started.
Frequently Asked Questions
Is phenazolam the same drug as clobromazolam?
Yes. Clobromazolam is an alternate name used for phenazolam in online markets and drug forums. It refers to the same compound, not a separate designer benzodiazepine.
Is phenazolam the same as bromazolam?
No. They are closely related but chemically distinct. Phenazolam has an additional chlorine atom compared with bromazolam. Both drugs may currently be circulating at the same time.
Is phenazolam the same as phenazepam?
No. Phenazepam is a different benzodiazepine. The similar spelling can create confusion, but forensic research lists phenazepam and clobromazolam as separate substances.
Is phenazolam stronger than bromazolam or Xanax?
There is not enough human research to establish a reliable dose equivalence. Laboratory modeling suggests clobromazolam may have high GABA-A receptor binding affinity, but that does not provide a safe human dose or a dependable comparison with Xanax or bromazolam.
Can Narcan reverse a phenazolam overdose?
Naloxone, commonly known by the brand name Narcan, does not reverse benzodiazepines. It should still be administered when opioid exposure is possible because phenazolam has been found in mixtures containing opioids. Call 911 even when the person responds to naloxone because dangerous benzodiazepine sedation may continue.
Will phenazolam appear on a regular drug test?
It may produce a positive benzodiazepine screen, but a routine confirmation panel may not identify the exact designer benzodiazepine. More specialized laboratory testing may be necessary.
Sources
Aegis Sciences Corporation. (2025). Emerging threat: Phenazolam (clobromazolam).
https://www.aegislabs.com/emerging-drug-trend/emerging-threat-phenazolam/
Center for Forensic Science Research and Education. (2025, December 19). Novel benzodiazepine phenazolam increasing in detections and prevalence among U.S. recreational drug markets.
https://www.cfsre.org/nps-discovery/public-alerts/novel-benzodiazepine-phenazolam-increasing-in-detections-and-prevalence-among-u-s-recreational-drug-markets
Drug Enforcement Administration. (2026, March 16). Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I. Federal Register.
https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i
Drug Enforcement Administration. (2026). DEA TOX First Quarter 2026 Report.
https://www.deadiversion.usdoj.gov/dea_tox/quarterly_reports/1st_Quarter_2026_DEA_TOX.pdf
Manchester, K. R., Waters, L., Haider, S., & Maskell, P. D. (2022). The blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines. Forensic Toxicology, 40(2), 349–356.
https://pubmed.ncbi.nlm.nih.gov/36454409/
Puzyrenko, A., Wang, D., Schneider, R., Wallace, G., Schreiber, S., Brandt, K., & Gunsolus, I. L. (2022). Urine drug screening in the era of designer benzodiazepines: Comparison of three immunoassay platforms, LC-QTOF-MS and LC-MS-MS. Journal of Analytical Toxicology.
https://pubmed.ncbi.nlm.nih.gov/34557900/
U.S. Food and Drug Administration. (2020). FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class
American Society of Addiction Medicine. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering.
https://www.asam.org/quality-care/clinical-guidelines/benzodiazepine-tapering
Centers for Disease Control and Prevention. (2021). Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines — 38 States and the District of Columbia, 2019–2020. MMWR.
https://www.cdc.gov/mmwr/volumes/70/wr/mm7034a4.htm
